OBJECTIVE: To assess the predictive capacity for the diagnosis of ventilator-associated pneumonia (VAP) of serum procalcitonin levels before and on the day it is suspected. DESIGN AND SETTING: Single-center observational study in the intensive care unit of a teaching hospital. PATIENTS AND PARTICIPANTS: Consecutive patients whose serum procalcitonin levels were available on the day that VAP was clinically suspected (day 1) and at some time within the preceding 5 days ("before"). MEASUREMENTS AND RESULTS: Serum procalcitonin levels were determined on day 1 and "before". Among the 73 suspected episodes VAP was confirmed by quantitative bronchoalveolar lavage cultures in 32 and refuted in 41. Respective median "before" procalcitonin levels were 1.89 ng/ml (interquartile range 0.18-6.01) and 2.14 (0.76-5.75) in patients with and without VAP, but their respective median day-1 procalcitonin levels did not differ: 1.07 ng/ml (0.39-6.57) vs. 1.40 (0.67-3.39). On day 1 a 0.5 ng/ml procalcitonin threshold had 72% sensitivity but only 24% specificity for diagnosing VAP. Between "before" and day 1, procalcitonin increased in 41% and 15% of patients with and without VAP, respectively. Thus a procalcitonin rise on day 1, compared to its "before" level, had 41% sensitivity and 85% specificity for diagnosing VAP, with respective positive and negative predictive values of 68% and 65%. CONCLUSIONS: Crude values and procalcitonin rise had poor diagnostic value for VAP in this particular setting and thus should not be used to initiate antibiotics when VAP is clinically suspected.
OBJECTIVE: To assess the predictive capacity for the diagnosis of ventilator-associated pneumonia (VAP) of serum procalcitonin levels before and on the day it is suspected. DESIGN AND SETTING: Single-center observational study in the intensive care unit of a teaching hospital. PATIENTS AND PARTICIPANTS: Consecutive patients whose serum procalcitonin levels were available on the day that VAP was clinically suspected (day 1) and at some time within the preceding 5 days ("before"). MEASUREMENTS AND RESULTS: Serum procalcitonin levels were determined on day 1 and "before". Among the 73 suspected episodes VAP was confirmed by quantitative bronchoalveolar lavage cultures in 32 and refuted in 41. Respective median "before" procalcitonin levels were 1.89 ng/ml (interquartile range 0.18-6.01) and 2.14 (0.76-5.75) in patients with and without VAP, but their respective median day-1 procalcitonin levels did not differ: 1.07 ng/ml (0.39-6.57) vs. 1.40 (0.67-3.39). On day 1 a 0.5 ng/ml procalcitonin threshold had 72% sensitivity but only 24% specificity for diagnosing VAP. Between "before" and day 1, procalcitonin increased in 41% and 15% of patients with and without VAP, respectively. Thus a procalcitonin rise on day 1, compared to its "before" level, had 41% sensitivity and 85% specificity for diagnosing VAP, with respective positive and negative predictive values of 68% and 65%. CONCLUSIONS: Crude values and procalcitonin rise had poor diagnostic value for VAP in this particular setting and thus should not be used to initiate antibiotics when VAP is clinically suspected.
Authors: Muriel Fartoukh; Bernard Maitre; Stephanie Honoré; Charles Cerf; Jean-Ralph Zahar; Christian Brun-Buisson Journal: Am J Respir Crit Care Med Date: 2003-05-08 Impact factor: 21.405
Authors: Mirjam Christ-Crain; Daiana Stolz; Roland Bingisser; Christian Müller; David Miedinger; Peter R Huber; Werner Zimmerli; Stephan Harbarth; Michael Tamm; Beat Müller Journal: Am J Respir Crit Care Med Date: 2006-04-07 Impact factor: 21.405
Authors: M S Dehoux; A Boutten; J Ostinelli; N Seta; M C Dombret; B Crestani; M Deschenes; J L Trouillet; M Aubier Journal: Am J Respir Crit Care Med Date: 1994-09 Impact factor: 21.405
Authors: A Boutten; M S Dehoux; N Seta; J Ostinelli; P Venembre; B Crestani; M C Dombret; G Durand; M Aubier Journal: Am J Respir Crit Care Med Date: 1996-01 Impact factor: 21.405
Authors: Andre C Kalil; Mark L Metersky; Michael Klompas; John Muscedere; Daniel A Sweeney; Lucy B Palmer; Lena M Napolitano; Naomi P O'Grady; John G Bartlett; Jordi Carratalà; Ali A El Solh; Santiago Ewig; Paul D Fey; Thomas M File; Marcos I Restrepo; Jason A Roberts; Grant W Waterer; Peggy Cruse; Shandra L Knight; Jan L Brozek Journal: Clin Infect Dis Date: 2016-07-14 Impact factor: 9.079
Authors: Boris Jung; Nathalie Embriaco; François Roux; Jean-Marie Forel; Didier Demory; Jérôme Allardet-Servent; Samir Jaber; Bernard La Scola; Laurent Papazian Journal: Intensive Care Med Date: 2010-03-09 Impact factor: 17.440